Top Markets
#1 ADO Protocol ADO Protocol +324.24%
#2 Islamic Coin Islamic Coin +155.41%
#3 GoPlus Security GoPlus Security +59.57%
#4 Starpower Starpower +34.32%
#5 Verus Coin Verus Coin +33.01%
#6 GAIB AID GAIB AID +24.67%
#7 Casper Network Casper Network +14.40%
#8 o1.exchange o1.exchange +12.87%
#9 Status Status +12.12%
#10 Lumia Lumia +10.89%
Coin of the day
ADO Protocol ADO Protocol
設定
言語
日本
通貨
USD
テーマ
CNS Pharmaceuticals, Inc. CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc.

CNSP
株式のランク #33273
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily... CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
株価
$5.47
最終同期: 2026-08-14
時価総額
$7.99M
変化（1日）
6.21%
変化（1年）
7.47%
国
US
取引 CNS Pharmaceuticals, Inc. (CNSP)

カテゴリー

Healthcare
CNS Pharmaceuticals, Inc.（CNSP）の収益
Aug 2026 時点の収益 TTM: 0
CNS Pharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
CNS Pharmaceuticals, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE